SCHEMBL6024050

SCHEMBL6024050

CCOC(=O)c1c(O)c(C=O)c(C)[nH]c1=O

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.69
USP2 O75604 1/20 0.56
CYP3A4 P08684 1/20 0.56
LMNA P02545 2/20 0.52
KDM4E B2RXH2 2/20 0.51
KDM5A P29375 1/20 0.51
KDM5B Q9UGL1 1/20 0.51
ALDH1A1 P00352 4/20 0.49
HPGD P15428 1/20 0.49
KMT2A Q03164 2/20 0.48
MAPT P10636 2/20 0.48
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26601966 0.82 LMNA (0.56) SMN1; SMN2LMNAKDM4EKDM5AKDM5B
SCHEMBL15331979 0.82 SMN1; SMN2 (1.00) SMN1; SMN2USP2CYP3A4LMNAKDM4E
SCHEMBL5188877 0.81 CYP1A2 (0.60) SMN1; SMN2LMNAKDM4EKDM5AKDM5B
SCHEMBL6023616 0.78 LMNA (0.52) SMN1; SMN2LMNAKDM4EKDM5AKDM5B
SCHEMBL8545504 0.75 HPGD (0.56) SMN1; SMN2USP2LMNAKDM4EALDH1A1
SCHEMBL2010227 0.74 CYP1A2 (0.52) SMN1; SMN2LMNAKDM4EALDH1A1HPGD
SCHEMBL68410 0.73 SMN1; SMN2 (0.71) SMN1; SMN2LMNAKDM4EALDH1A1HPGD
SCHEMBL1801531 0.72 HPGD (0.69) SMN1; SMN2LMNAALDH1A1HPGDKMT2A
SCHEMBL11789541 0.72 SMN1; SMN2 (0.65) SMN1; SMN2LMNAKDM4EALDH1A1HPGD
Ethyl Hematommate SCHEMBL31350971 0.72 CYP3A4 (1.00) SMN1; SMN2USP2CYP3A4LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115608-B2 Pyridinone and pyridinethione derivatives having HIV inhibiting properties CENTRE NATIONAL DE LA RECHERCHE SCHENTIFIQUE (FR) 2006-10-03 US disclosed
EP-1318995-B1 PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES CENTRE NAT RECH SCIENT (FR) 2006-03-08 EP disclosed
US-20040229847-A1 Pyridinone and pyridinethione derivatives having hiv inhibiting properties CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2004-11-18 US disclosed
EP-1318995-A2 PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2003-06-18 EP disclosed
WO-2002024650-A2 PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229847-A1 Pyridinone and pyridinethione derivatives having hiv inhibiting properties CYP2B6, CYP2S1, CYP2D6 SMN1; SMN2 4627/4885USP2 4294/4885CYP3A4 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.